Trial Profile
A phase II study of irinotecan (CPT-11) and docetaxel (Taxotere) in patients with recurrent non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2015
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Jan 2007 Status changed from in progress to completed
- 04 Sep 2005 New trial record.